Decibel Therapeutics has been granted a patent for hypertonic pharmaceutical compositions containing anti-platinum chemoprotectant agents and gelling agents. The compositions have a calculated osmolarity of 3,000-7,000 mOsm/L. The patent also covers methods of medical use for these compositions. GlobalData’s report on Decibel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Decibel Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents. Decibel Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Hypertonic pharmaceutical composition for anti-platinum chemoprotection
A recently granted patent (Publication Number: US11857567B2) discloses a hypertonic pharmaceutical composition designed to prevent or mitigate platinum-induced ototoxicity in subjects. The composition, with a calculated osmolarity ranging from 3,000 to 7,000 mOsm/L, consists of 1M-2M of an anti-platinum chemoprotectant agent, a gelling agent, and an optional tonicity agent. The osmolarity is calculated based on the chemoprotectant agent and tonicity agent, if included. The anti-platinum chemoprotectant agent can be various substances such as alkaline thiosulfate salts, amifostine, methionine, or glutathione, among others. The gelling agent options include hyaluronan, polyethylene glycol, cellulose derivatives, and more, with hyaluronan being a preferred choice.
Moreover, the patent outlines a method for administering the hypertonic pharmaceutical composition intratympanically or transtympanically to the round window of the subject to effectively prevent or mitigate platinum-induced ototoxicity. The composition can be administered before or after the subject receives a platinum-based antineoplastic agent, and the dosage form can vary based on the route of administration. The preparation method involves mixing the anti-platinum chemoprotectant agent, gelling agent, and optional tonicity agent with a liquid solvent to achieve the desired hypertonic pharmaceutical composition. The patent also specifies variations of the composition, such as one with a calculated osmolarity of 3,000-5,000 mOsm/L, comprising sodium thiosulfate as the chemoprotectant agent and hyaluronan as the gelling agent, further emphasizing the importance of these components in the formulation.
To know more about GlobalData’s detailed insights on Decibel Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
